Dezocine
As of the edition of 20 October 2026, Dezocine is a small molecule: marketed, first approved in 1989 (US); acts on OPRK1 and OPRM1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Dalgan
- First approved
- 29 December 1989 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- AstraZeneca
- Registered trials
- 10, 0 stopped early
- Disease areas
- Nervous system; Cancer; Digestive system; Mental health; Skin and connective tissue
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Dezocine.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 1 | 1 | 0 |
| Phase 4 | 5 | 2 | 0 | 0 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Astra | Earlier holder | 1989 to now |
| AstraZeneca | Acquired holder | 2003 to now |